Stay updated on Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page
- Check7 days agoChange DetectedThe page revision tag changed from v3.6.4 to v3.6.5, signaling a new deployment/version of the page. This appears to be an administrative update and does not alter the study data or visible content.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page shows a new revision number, signaling a backend or UI update to the page. No study details or results are altered.SummaryDifference0.0%

- Check28 days agoNo Change Detected
- Check50 days agoChange DetectedA revision tag v3.6.3 was added and the previous tag v3.6.0 was removed, indicating an update to the page's revision metadata.SummaryDifference0.0%

- Check64 days agoChange DetectedNew user guidance sections and a recruitment status update were added to the study page, clarifying participation options and how to navigate the record. A formatting tweak to the Intervention/Treatment heading and the revision label were updated.SummaryDifference0.4%

- Check71 days agoChange DetectedThe page revision was updated to v3.5.5, indicating an internal update to the page rendering or content management system.SummaryDifference0.0%

- Check85 days agoChange DetectedAdded update dates 2026-05-20, 2026-05-05, and 2026-05. Removed 2025-11-18, 2025-11-05, and 2025-11, reflecting changes to the page's revision history.SummaryDifference0.2%

Stay in the know with updates to Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page.